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The role of metformin in cardiovascular disease is 
under investigation. Aside from its established use for 
patients with type 2 diabetes, metformin is thought to 
be beneﬁ cial for cardiovascular disease, although solid 
evidence is lacking. The alleged protective eﬀ ects of 
metformin in cardiovascular disease seem at least partly 
unrelated to its eﬀ ects on glucose metabolism. The 
investigators of the Carotid Atherosclerosis: MEtformin 
for insulin ResistAnce (CAMERA) study1 investigated the 
eﬀ ect of metformin on carotid intima-media thickness 
(cIMT) in a double-blind randomised controlled trial of 
173 patients with proven coronary heart disease, but 
without diabetes. After 18 months, cIMT progression 
did not diﬀ er signiﬁ cantly between metformin and 
placebo groups (slope diﬀ erence 0·007 mm per year, 
95% CI –0·006 to 0·020; p=0·29) The investigators did 
report a reduction in HbA1c or insulin concentrations in 
patients assigned to metformin compared with those 
assigned to placebo.
Patients in the study had coronary heart disease and 
were therefore treated according to current guidelines, 
with all patients taking statins. Thus, the window of 
opportunity for improving atherosclerosis as measured 
by cIMT was small. The study was powered to detect 
a diﬀ erence in cIMT between the metformin and 
control groups of 0·021 mm after 18 months. This 
diﬀ erence was partly based on the study of Meaney 
and colleagues2 in which 40 patients with features 
of metabolic syndrome were either treated with 
metformin or received no additional treatment. After 
12 months, patients in the metformin group had a 
greater reduction of cIMT than in the control group 
(–0·1 mm, p=0·04 vs –0·02 mm, p=not signiﬁ cant). 
By contrast with patients in CAMERA, patients in the 
study by Meaney and colleagues2 had higher baseline 
LDL-cholesterol, and data for use of statins were 
not presented, so the potential for cIMT reduction 
was probably greater. Katakami and colleagues3 
also studied the eﬀ ect of metformin on cIMT. They 
assessed 118 patients with type 2 diabetes treated with 
glibenclamide over 3 years. Addition of metformin was 
associated with less progression of cIMT compared with 
placebo (0·003 mm vs 0·064 mm; p<0·0001). However, 
few patients (n=29) were taking statins. The studies by 
Meaney and colleagues and Katakami and colleagues 
show that metformin might reduce progression of 
cIMT in the absence of statin treatment. The CAMERA 
study shows that the eﬀ ect of metformin—in addition 
to current best treatment, including statins—on cIMT is 
probably small or negligible. In two upcoming trials, the 
Copenhagen Insulin and Metformin Therapy trial (CIMT; 
NCT00657943) and the REducing with MetfOrmin 
Vascular Adverse Lesions in type 1 diabetes trial 
(REMOVAL; NCT01483560), the eﬀ ect of metformin 
on cIMT will be assessed in 500 patients with 
type 1 diabetes and 950 patients with type 2 diabetes 
in whom statin use will be monitored, respectively.4 We 
are interested to see whether these studies will show a 
beneﬁ cial eﬀ ect of metformin in addition to statins. 
Proof-of-principle trials such as CAMERA are usually 
powered to assess markers thought to be reliable 
proxies for outcomes. Ideally, a strong causal relation 
exists between the surrogate endpoint and outcome. 
cIMT is an established marker for the diagnosis of 
atherosclerotic disease, and a surrogate approved by 
the US Food and Drug Administration. Conversely, 
little evidence exists of a direct association between 
improvement of cIMT and outcome. Moreover, the 
experimental evidence for a direct eﬀ ect of metformin 
on cIMT is weak.5 Experimental evidence of an eﬀ ect on 
myocardial function is more established: several studies 
show that metformin is associated with a reduced 
size of myocardial infarct.6 Furthermore, metformin 
exerts anti-thrombotic eﬀ ects, which could explain 
the improved outcome in atherothrombotic disease.7 
Likewise, in a non-ischaemic experimental study of 
rats, metformin prevented heart failure and improved 
myocardial function, suggesting that metformin 
might even improve myocardial function irrespective 
of ischaemia.8 In several retrospective analyses9,10 of 
patients with diabetes with concomitant coronary 
artery disease and even heart failure, use of metformin 
was associated with improved survival independent 
of glycaemic control. Ongoing randomised, double-
blind clinical trials such as the Metformin in CABG trial 
(MetCAB; NCT01438723) and the Glycometabolic 
Intervention as Adjunct to Primary Percutaneous 
Intervention in ST Elevation Myocardial Infarction 
Trial (GIPS-III; NCT01217307) will elucidate whether 
metformin can reduce myocardial infarct size, improve 
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resilience to ischaemia, and improve left ventricular 
function after ischaemia-reperfusion injury. Like cIMT, 
the eﬀ ect of metformin on myocardial function and 
infarct size is also a surrogate endpoint for clinical 
outcome.
Whether the primary endpoint of CAMERA or 
secondary endpoints such as HbA1c best represent 
cardiovascular outcome is unclear. The deﬁ nitive 
evidence for the role of metformin in non-diabetic 
cardiovascular disease will have to be provided by large 
randomised clinical trials powered for cardiovascular 
outcomes such as the Glucose Lowering In Non-diabetic 
hyperglycaemia Trial (GLINT; ISRCTN34875079), in 
which 12 000 patients with high cardiovascular risk and 
dysglycaemia but without diabetes, will be assigned to 
metformin or placebo for 5 years. Until then, the role of 
metformin for improving cardiovascular outcomes has 
promise, but is still largely unproven. 
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The importance of incretin therapies for managing 
type 2 diabetes 
A quarter of a century after the discovery of incretin 
hormones and their impaired regulation of insulin 
and glucagon secretion in type 2 diabetes,1 speciﬁ c 
treatments to improve the diminished incretin eﬀ ect 
have become widely available for glycaemic control in 
type 2 diabetes. Incretin treatments consist of either 
oral DPP-4 inhibitors, which decrease the clearance of 
secreted incretins GLP-1 and GIP, or injectable analogues 
of GLP-1. Relative freedom from hypoglycaemia, an 
absence of weight gain, and additivity in glucose control 
in combination with metformin have largely driven the 
increasing acceptance of these drugs.2,3
Despite the proliferation of many new drugs for 
diabetes management, low persistence and adherence 
of patients to these drugs remain key drivers of 
residual hyperglycaemia in this population. Increasing 
complexity of therapeutic interventions is one key 
reason for low adherence.4 For this reason, the use of 
combination treatments  for managing type 2 diabetes 
is increasingly common, since reducing the number of 
tablets per day by combining two agents into a single 
tablet reduces complexity of treatment for the patient.3 
Because the once daily DPP-4 inhibitors can be used in 
combination with long-acting metformin preparations, 
this combination eﬀ ectively reduces the pill burden for 
many patients, especially those with early, asymptomatic 
type 2 diabetes, in which many patients believe their 
therapies to be somewhat optional.
Another strategy to increase adherence and 
persistence is to reduce the frequency of medication 
administration. Thus, once-daily medications seem 
preferable to those  that must be administered 
twice or three-times daily. Recently, once weekly 
drugs have begun to make an appearance in the 
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